GlaxoSmithKline has taken the wraps off its new, $600 million vaccine manufacturing plant in Singapore, which will produce jabs for a range of childhood diseases such as meningitis, pneumonia and blood poisoning. And the opening ceremony featured plenty of boasting. Glaxo chief Andrew Witty called the plant "possibly the best vaccine facility anywhere in the world." GSK report